Christopher Waddick
Vermogen: 144 054 $ op 30-06-2026
Vermogen: 144 054 $ op 30-06-2026
Christopher J.
Waddick is Chief Financial Officer, Secretary & Director at Cardiol Therapeutics, Inc. since 2022, President & Chief Financial Officer at Active Energy, Inc. since 2013, and President at Nrj Consulting, Inc. since 2009.
Formerly, Mr. Waddick was Chief Financial & Executive Officer at Vasogen, Inc. from 2007 to 2009.
Education includes an MBA from York University and an undergraduate degree from Wilfrid Laurier University.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 30-12-2025 | 135.900 ( 0,12% ) | 144 054 $ | 30-06-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| CARDIOL THERAPEUTICS INC. | Financieel Directeur/CFO | 16-08-2018 |
Active Energy, Inc.
Active Energy, Inc. Electric UtilitiesUtilities Supplies natural gas and electricity | Financieel Directeur/CFO | 01-01-2013 |
Nrj Consulting, Inc. | President | 01-11-2009 |
| Bedrijven | Functie | Einde |
|---|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures drugs to treat cardiovascular and neurodegenerative disorders | Algemeen Directeur | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 6 |
|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures drugs to treat cardiovascular and neurodegenerative disorders | Health Technology |
York University
York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wilfrid Laurier University
Wilfrid Laurier University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Active Energy, Inc.
Active Energy, Inc. Electric UtilitiesUtilities Supplies natural gas and electricity | Utilities |
Cardiol Therapeutics, Inc.
Cardiol Therapeutics, Inc. BiotechnologyHealth Technology Operates as a life sciences company that researches and develops antifibrotic and anti-inflammatory therapy for the treatment of cardiovascular disease | Health Technology |
Nrj Consulting, Inc. |
Kies jouw editie
Alle financiële informatie op nationaal niveau